Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. DLG4-related synaptopathy: a new rare brain disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. NEXMIF encephalopathy: an X-linked disorder with male and female phenotypic patterns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. DOORS syndrome and a recurrent truncating ATP6V1B2 variant

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. The influence of marital status and partner concordance on participation in colorectal cancer screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. New Pathogenic Germline Variants in Very Early Onset and Familial Colorectal Cancer Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Mev Dominguez-Valentin
  • Emma J Crosbie
  • Christoph Engel
  • Stefan Aretz
  • Finlay Macrae
  • Ingrid Winship
  • Gabriel Capella
  • Huw Thomas
  • Sigve Nakken
  • Eivind Hovig
  • Maartje Nielsen
  • Rolf H Sijmons
  • Lucio Bertario
  • Bernardo Bonanni
  • Maria Grazia Tibiletti
  • Giulia Martina Cavestro
  • Miriam Mints
  • Nathan Gluck
  • Lior Katz
  • Karl Heinimann
  • Carlos A Vaccaro
  • Kate Green
  • Fiona Lalloo
  • James Hill
  • Wolff Schmiegel
  • Deepak Vangala
  • Claudia Perne
  • Hans-Georg Strauß
  • Johanna Tecklenburg
  • Elke Holinski-Feder
  • Verena Steinke-Lange
  • Jukka-Pekka Mecklin
  • John-Paul Plazzer
  • Marta Pineda
  • Matilde Navarro
  • Joan Brunet Vidal
  • Revital Kariv
  • Guy Rosner
  • Tamara Alejandra Piñero
  • María Laura Gonzalez
  • Pablo Kalfayan
  • Neil Ryan
  • Sanne W Ten Broeke
  • Mark A Jenkins
  • Lone Sunde
  • Inge Bernstein
  • John Burn
  • Marc Greenblatt
  • Wouter H de Vos Tot Nederveen Cappel
  • Adriana Della Valle
  • Francisco Lopez-Koestner
  • Karin Alvarez
  • Reinhard Büttner
  • Heike Görgens
  • Monika Morak
  • Stefanie Holzapfel
  • Robert Hüneburg
  • Magnus von Knebel Doeberitz
  • Markus Loeffler
  • Nils Rahner
  • Jürgen Weitz
  • Kirsi Pylvänäinen
  • Laura Renkonen-Sinisalo
  • Anna Lepistö
  • Annika Auranen
  • John L Hopper
  • Aung Ko Win
  • Robert W Haile
  • Noralane M Lindor
  • Steven Gallinger
  • Loïc Le Marchand
  • Polly A Newcomb
  • Jane C Figueiredo
  • Stephen N Thibodeau
  • Christina Therkildsen
  • Henrik Okkels
  • Zohreh Ketabi
  • Oliver G Denton
  • Einar Andreas Rødland
  • Hans Vasen
  • Florencia Neffa
  • Patricia Esperon
  • Douglas Tjandra
  • Gabriela Möslein
  • Julian R Sampson
  • D Gareth Evans
  • Toni T Seppälä
  • Pål Møller
Vis graf over relationer

PURPOSE: To determine impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) on gynecological cancer incidence and death in heterozygotes of pathogenic MMR (path_MMR) variants.

METHODS: The Prospective Lynch Syndrome Database was used to investigate the effects of gynecological risk-reducing surgery (RRS) at different ages.

RESULTS: Risk-reducing hysterectomy at 25 years of age prevents endometrial cancer before 50 years in 15%, 18%, 13%, and 0% of path_MLH1, path_MSH2, path_MSH6, and path_PMS2 heterozygotes and death in 2%, 2%, 1%, and 0%, respectively. Risk-reducing BSO at 25 years of age prevents ovarian cancer before 50 years in 6%, 11%, 2%, and 0% and death in 1%, 2%, 0%, and 0%, respectively. Risk-reducing hysterectomy at 40 years prevents endometrial cancer by 50 years in 13%, 16%, 11%, and 0% and death in 1%, 2%, 1%, and 0%, respectively. BSO at 40 years prevents ovarian cancer before 50 years in 4%, 8%, 0%, and 0%, and death in 1%, 1%, 0%, and 0%, respectively.

CONCLUSION: Little benefit is gained by performing RRS before 40 years of age and premenopausal BSO in path_MSH6 and path_PMS2 heterozygotes has no measurable benefit for mortality. These findings may aid decision making for women with LS who are considering RRS.

OriginalsprogEngelsk
TidsskriftGenetics In Medicine
ISSN1098-3600
DOI
StatusUdgivet - 1 dec. 2020

ID: 61405533